Abstract
In the past few years accumulating evidence involved chromosomal instability and the subsequent aneuploidy that it generates in tumor formation. Moreover, the misregulation of most of the proteins involved in the mitotic checkpoint as well as kinetochore assembly has proven to have tumorigenic potential in vivo. Thus, the overexpression of Ndc80/Hec1, an outer kinetochore protein involved in spindle assembly checkpoint (SAC) recruitment, has been shown to induce tumor formation in different organs. Since Ndc80/Hec1 is a protein “ highly expressed in cancer” , it is an attractive target that can be used for cancer therapy. In this direction, several strategies aiming to in vivo block this complex structure and activity are being developed, and some of them have demonstrated to have tumor growth inhibition potential. These therapies represent a potential interesting approach for the treatment of malignancies where Ndc80/Hec1 expression is upregulated. Here we will discuss different aspects of Ndc80/Hec1 biology, its role in kinetochore assembly and spindle checkpoint, and its importance as a potential therapeutical target.
Keywords: Ndc80, Hec1, Kinetochores, spindle checkpoint, aneuploidy, cancer
Current Drug Therapy
Title: Targeting the Kinetochore in Cancer Therapy: The Ndc80/Hec1 Complex
Volume: 5 Issue: 1
Author(s): Elena Diaz-Rodriguez
Affiliation:
Keywords: Ndc80, Hec1, Kinetochores, spindle checkpoint, aneuploidy, cancer
Abstract: In the past few years accumulating evidence involved chromosomal instability and the subsequent aneuploidy that it generates in tumor formation. Moreover, the misregulation of most of the proteins involved in the mitotic checkpoint as well as kinetochore assembly has proven to have tumorigenic potential in vivo. Thus, the overexpression of Ndc80/Hec1, an outer kinetochore protein involved in spindle assembly checkpoint (SAC) recruitment, has been shown to induce tumor formation in different organs. Since Ndc80/Hec1 is a protein “ highly expressed in cancer” , it is an attractive target that can be used for cancer therapy. In this direction, several strategies aiming to in vivo block this complex structure and activity are being developed, and some of them have demonstrated to have tumor growth inhibition potential. These therapies represent a potential interesting approach for the treatment of malignancies where Ndc80/Hec1 expression is upregulated. Here we will discuss different aspects of Ndc80/Hec1 biology, its role in kinetochore assembly and spindle checkpoint, and its importance as a potential therapeutical target.
Export Options
About this article
Cite this article as:
Diaz-Rodriguez Elena, Targeting the Kinetochore in Cancer Therapy: The Ndc80/Hec1 Complex, Current Drug Therapy 2010; 5 (1) . https://dx.doi.org/10.2174/1574885511005010029
DOI https://dx.doi.org/10.2174/1574885511005010029 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets Retinoblastoma Regulatory Pathway in Lung Cancer
Current Molecular Medicine The Use of Vitamin D in Respiratory Diseases
Current Respiratory Medicine Reviews Pharmacology of TRP Channels in the Vasculature
Current Vascular Pharmacology MicroRNAs in the Pathobiology of Multiple Myeloma
Current Cancer Drug Targets Possible Physiopathological Effects of the Transglutaminase Activity on the Molecular Mechanisms Responsible for Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry HPV Viral Activity by mRNA-HPV Molecular Analysis to Screen the Transforming Infections in Precancer Cervical Lesions
Current Pharmaceutical Biotechnology Applications of Nucleic Acid Drugs for Organ Transplantation
Current Topics in Medicinal Chemistry Emerging Roles of Meis1 in Cardiac Regeneration, Stem Cells and Cancer
Current Drug Targets mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design Thiazolidinediones Anti-Inflammatory and Anti-Atherosclerotic Effects in Type 2 Diabetes Mellitus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Molecular Dynamics, Density Functional Theory, Pharmacophore Modeling, Molecular Interaction Fields and ADME/Tox Investigation of Novel Bioactive Compounds Interacting with CDK2 Surfaces
Current Physical Chemistry Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Role of Genetics and Epigenetics in Mucosal, Uveal, and Cutaneous Melanomagenesis
Anti-Cancer Agents in Medicinal Chemistry Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets